Our findings provide new insight into the molecular mechanisms of apoptosis resistance in sorafenib treatment and suggest that melatonin may be a promising agent and that the PERK-ATF4-Beclin1 pathway may be a target for the treatment of HCC. This evidence concerns the gene BECN1 and hepatocellular carcinoma.